Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.33 |
| ▸ | S100A4 | P26447 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | WDR5 | P61964 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10439981 | 0.79 | CA12 (0.33) | S100A4 | |
| SCHEMBL2167752 | 0.79 | CA2 (0.40) | S100A4 | |
| SCHEMBL941266 | 0.77 | G6PD (0.37) | ALDH1A1 | |
| SCHEMBL2168627 | 0.77 | CA1 (0.34) | — | |
| SCHEMBL28023854 | 0.75 | — | — | |
| SCHEMBL5868198 | 0.75 | L3MBTL1 (0.42) | ALDH1A1 | |
| SCHEMBL751917 | 0.75 | CCR2 (0.34) | S100A4 | |
| SCHEMBL1116610 | 0.75 | PTGS2 (0.38) | — | |
| SCHEMBL5644771 | 0.72 | MAPT (0.35) | ALDH1A1 | |
| SCHEMBL3930133 | 0.72 | PTGS2 (0.37) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4716984-B2 | — | — | 2011-07-06 | — | — | JP | claimed |
| EP-1809600-A4 | CYCLIC B-AMINO ACID DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2009-01-14 | — | — | EP | claimed |
| EP-1667647-A4 | MONOCYCLIC AND BICYCLIC LACTAMS AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2008-10-22 | — | — | EP | claimed |
| EP-1603572-A4 | LACTAM-CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2008-06-25 | — | — | EP | claimed |
| EP-1670739-A4 | CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2007-08-08 | — | — | EP | claimed |
| EP-1809600-A2 | CYCLIC B-AMINO ACID DERIVATIVES AS FACTOR XA INHIBITORS | Bristol-Myers Squibb Company (US) | 2007-07-25 | — | — | EP | claimed |
| US-20070135428-A1 | LACTAM CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS | QIAO JENNIFER X | 2007-06-14 | — | — | US | claimed |
| US-7205318-B2 | Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-17 | — | — | US | claimed |
| US-7115646-B2 | Cyclic diamines and derivatives as factor Xa inhibitors | BRISTOL MYERS SQUIBB, CO. (US) | 2006-10-03 | — | — | US | claimed |
| JP-2006520790-A | — | — | 2006-09-14 | — | — | JP | claimed |
| EP-1603572-A1 | LACTAM-CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-12-14 | — | — | EP | claimed |
| US-20050107361-A1 | Monocyclic and bicyclic lactams as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMANY | 2005-05-19 | — | — | US | claimed |
| US-20050085511-A1 | Cyclic diamines and derivatives as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-04-21 | — | — | US | claimed |
| WO-2005032490-A2 | CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-04-14 | — | — | WO | claimed |
| WO-2005032468-A2 | MONOCYCLIC AND BICYCLIC LACTAMS AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-04-14 | — | — | WO | claimed |
| EP-1505966-A1 | 1,1-DISUBSTITUTED CYCLOALKYL DERIVATIVES AS FACTOR XA INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-02-16 | — | — | EP | claimed |
| US-20040254158-A1 | Anticoagulants; atherosclerosis; strokes; thrombosis; cardiovascular disorders | BRISTOL-MYERS SQUIBB COMPANY | 2004-12-16 | — | — | US | claimed |
| US-20040204454-A1 | Lactam-containing cyclic diamines and derivatives as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-14 | — | — | US | claimed |
| WO-2004082687-A1 | LACTAM-CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-09-30 | — | — | WO | claimed |
| WO-2003099276-A1 | 1,1-DISUBSTITUTED CYCLOALKYL DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-04 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135428-A1 | LACTAM CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS | F12, F2, PEPD | SLC22A12 2857/4885S100A4 1785/4885ALDH1A1 3204/4885 |
| US-20040254158-A1 | Anticoagulants; atherosclerosis; strokes; thrombosis; cardiovascular disorders | SERPINC1, PCSK9, PLAT | SLC22A12 1403/4885S100A4 3778/4885ALDH1A1 2197/4885 |
| US-20040204454-A1 | Lactam-containing cyclic diamines and derivatives as factor Xa inhibitors | PEPD, TFPI, F2 | SLC22A12 2973/4885S100A4 1308/4885ALDH1A1 3153/4885 |
| US-20050085511-A1 | Cyclic diamines and derivatives as factor Xa inhibitors | TFPI, SERPINC1, F12 | SLC22A12 1367/4885S100A4 4002/4885ALDH1A1 2579/4885 |
| US-20050107361-A1 | Monocyclic and bicyclic lactams as factor Xa inhibitors | F2, F12, SPINT2 | SLC22A12 2082/4885S100A4 2792/4885ALDH1A1 2842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.